Successful treatment of refractory adult-onset still disease with canakinumab: A case report

Journal of Clinical Rheumatology

Volumn 20, Issue 2, 2014, Pages 121-

  Barsotti, Simone ^a   Neri, Rossella ^a   Iacopetti, Valentina ^b   D'Ascanio, Anna ^a   Talarico, Rosaria ^a   Tripoli, Alessandra ^a   Bombardieri, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Internal Medicine   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CANAKINUMAB; CYTOKINE; ETANERCEPT; FERRITIN; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB;

ADULT; ADULT ONSET STILL DISEASE; ARTHRITIS; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LETTER; LOW DRUG DOSE; MEASLES LIKE RASH; PHARYNGITIS; PRIORITY JOURNAL; REMISSION; SHIVERING; SYSTEMIC DISEASE; TREATMENT RESPONSE; YOUNG ADULT;

ANTIRHEUMATIC AGENTS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; STILL'S DISEASE, ADULT-ONSET;

EID: 84896722588     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000082     Document Type: Letter

References (8)

1. Debiais S, Maillot F, Luca L, et al. Efficacy of anakinra in a case of refractory Still disease. J Clin Rheumatol. 2008;14: 357-358.
2. Kontzias A, Efthimiou P. The use of canakinumab, a novel IL-1A long-acting inhibitor, in refractory adult-onset Still's disease. Semin Arthritis Rheum. 2012;42:201-205.
3. Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. Arthritis Rheum. 2010;62:2530-2535.
4. Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford). 2001;40:1398-1404.
5. Fitzgerald AA, LeClercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005;52:1794-1803.
6. Naumann L, Feist E, Natusch A, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis. 2010;69:466-467.
7. Dhimolea E. Canakinumab. MAbs. 2010;2:3-13.
8. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416-2425.